A Phase 1, First in Human, Randomized, Double-blind, Placebo Controlled Study of the Safety, Tolerability, and Immunogenicity of the CodaVax-RSV Vaccine in Healthy Adult Volunteers
Latest Information Update: 14 Jun 2021
At a glance
- Drugs MinL 4.0 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Codagenix
Most Recent Events
- 08 Jun 2021 Status changed from active, no longer recruiting to completed.
- 24 May 2021 Planned End Date changed from 11 May 2021 to 26 May 2021.
- 26 Jan 2021 Planned End Date changed from 11 Jan 2021 to 11 May 2021.